Literature DB >> 23183335

Novel excitation-contraction uncoupled RYR1 mutations in patients with central core disease.

Natalia Kraeva1, Elena Zvaritch, Ann E Rossi, Sanjeewa A Goonasekera, Hilal Zaid, Wanda Frodis, Alexander Kraev, Robert T Dirksen, David H Maclennan, Sheila Riazi.   

Abstract

Central core disease, one of the most common congenital myopathies in humans, has been linked to mutations in the RYR1 gene encoding the Ca(2+) release channel of the sarcoplasmic reticulum (RyR1). Functional analyses showed that disease-associated RYR1 mutations led to impairment of skeletal muscle Ca(2+) homeostasis; however, thorough understanding of the molecular mechanisms underlying central core disease and other RyR1-related conditions is still lacking. We screened by sequencing the complete RYR1 transcripts in ten unrelated patients with central core disease and identified five novel, p.M4640R, p.L4647P, p.F4808L, p.D4918N and p.F4941C, and four recurrent mutations. Four of the novel mutations involved amino acid residues that were positioned within putative transmembrane segments of the RyR1. The pathogenic character of the identified mutations was demonstrated by bioinformatic analyses and by the in vitro functional studies in HEK293 cells and RYR1-null (dyspedic) myotubes. Characterization of Ca(2+) channel properties of RyR1s carrying one recurrent and two novel mutations upholds the view that diminished intracellular Ca(2+) release caused by impaired Ca(2+) channel gating and/or Ca(2+) permeability is an important component of central core disease etiology. This study expands the list of functionally characterized disease-associated RyR1 mutations, increasing the value of genetic diagnosis for RyR1-related disorders. Crown
Copyright © 2012. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23183335      PMCID: PMC3563839          DOI: 10.1016/j.nmd.2012.08.007

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  53 in total

1.  The spectrum of pathology in central core disease.

Authors:  C A Sewry; C Müller; M Davis; J S M Dwyer; J Dove; G Evans; R Schröder; D Fürst; T Helliwell; N Laing; R C M Quinlivan
Journal:  Neuromuscul Disord       Date:  2002-12       Impact factor: 4.296

2.  Central core disease mutations R4892W, I4897T and G4898E in the ryanodine receptor isoform 1 reduce the Ca2+ sensitivity and amplitude of Ca2+-dependent Ca2+ release.

Authors:  Guo Guang Du; Vijay K Khanna; Xinghua Guo; David H MacLennan
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

3.  Frequency and localization of mutations in the 106 exons of the RYR1 gene in 50 individuals with malignant hyperthermia.

Authors:  Lucia Galli; Alfredo Orrico; Stefania Lorenzini; Stefano Censini; Michela Falciani; Antonello Covacci; Vincenzo Tegazzin; Vincenzo Sorrentino
Journal:  Hum Mutat       Date:  2006-08       Impact factor: 4.878

4.  A mutation in the transmembrane/luminal domain of the ryanodine receptor is associated with abnormal Ca2+ release channel function and severe central core disease.

Authors:  P J Lynch; J Tong; M Lehane; A Mallet; L Giblin; J J Heffron; P Vaughan; G Zafra; D H MacLennan; T V McCarthy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

5.  Screening of the ryanodine 1 gene for malignant hyperthermia causative mutations by high resolution melt curve analysis.

Authors:  Marcus Broman; Kai Heinecke; Gunilla Islander; Frank Schuster; Klaus Glahn; Mikael Bodelsson; Susan Treves; Clemens Müller
Journal:  Anesth Analg       Date:  2011-09-30       Impact factor: 5.108

6.  Ryanodine receptor type 1 gene mutations found in the Canadian malignant hyperthermia population.

Authors:  Natasha Kraeva; Sheila Riazi; Julian Loke; Wanda Frodis; Mary Lou Crossan; Kevin Nolan; Alexander Kraev; David H Maclennan
Journal:  Can J Anaesth       Date:  2011-03-31       Impact factor: 5.063

7.  Familial and sporadic forms of central core disease are associated with mutations in the C-terminal domain of the skeletal muscle ryanodine receptor.

Authors:  N Monnier; N B Romero; J Lerale; P Landrieu; Y Nivoche; M Fardeau; J Lunardi
Journal:  Hum Mol Genet       Date:  2001-10-15       Impact factor: 6.150

8.  Single-channel properties of the recombinant skeletal muscle Ca2+ release channel (ryanodine receptor).

Authors:  S R Chen; P Leong; J P Imredy; C Bartlett; L Zhang; D H MacLennan
Journal:  Biophys J       Date:  1997-10       Impact factor: 4.033

9.  Ca2+ dysregulation in Ryr1(I4895T/wt) mice causes congenital myopathy with progressive formation of minicores, cores, and nemaline rods.

Authors:  Elena Zvaritch; Natasha Kraeva; Eric Bombardier; Robert A McCloy; Frederic Depreux; Douglas Holmyard; Alexander Kraev; Christine E Seidman; J G Seidman; A Russell Tupling; David H MacLennan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-03       Impact factor: 11.205

Review 10.  Pathological defects in congenital myopathies.

Authors:  Caroline A Sewry
Journal:  J Muscle Res Cell Motil       Date:  2008-12-30       Impact factor: 2.698

View more
  14 in total

Review 1.  Muscle MRI in pediatrics: clinical, pathological and genetic correlation.

Authors:  Claudia P Cejas; Maria M Serra; David F Gonzalez Galvez; Eliana A Cavassa; Ana L Taratuto; Gabriel A Vazquez; Mario E L Massaro; Angeles V Schteinschneider
Journal:  Pediatr Radiol       Date:  2017-01-19

2.  Comparison of pathogenicity prediction tools on missense variants in RYR1 and CACNA1S associated with malignant hyperthermia.

Authors:  A H Schiemann; K M Stowell
Journal:  Br J Anaesth       Date:  2016-05-04       Impact factor: 9.166

3.  Oxidative stress, mitochondrial damage, and cores in muscle from calsequestrin-1 knockout mice.

Authors:  Cecilia Paolini; Marco Quarta; Lan Wei-LaPierre; Antonio Michelucci; Alessandra Nori; Carlo Reggiani; Robert T Dirksen; Feliciano Protasi
Journal:  Skelet Muscle       Date:  2015-04-18       Impact factor: 4.912

Review 4.  The couplonopathies: A comparative approach to a class of diseases of skeletal and cardiac muscle.

Authors:  Eduardo Ríos; Lourdes Figueroa; Carlo Manno; Natalia Kraeva; Sheila Riazi
Journal:  J Gen Physiol       Date:  2015-06       Impact factor: 4.086

5.  Aging Effects of Caenorhabditis elegans Ryanodine Receptor Variants Corresponding to Human Myopathic Mutations.

Authors:  Baines K Nicoll; Célia Ferreira; Philip M Hopkins; Marie-Anne Shaw; Ian A Hope
Journal:  G3 (Bethesda)       Date:  2017-05-05       Impact factor: 3.154

6.  Functional Characterization of C-terminal Ryanodine Receptor 1 Variants Associated with Central Core Disease or Malignant Hyperthermia.

Authors:  Remai Parker; Anja H Schiemann; Elaine Langton; Terasa Bulger; Neil Pollock; Andrew Bjorksten; Robyn Gillies; David Hutchinson; Richard Roxburgh; Kathryn M Stowell
Journal:  J Neuromuscul Dis       Date:  2017

7.  Correlation of phenotype with genotype and protein structure in RYR1-related disorders.

Authors:  Joshua J Todd; Vatsala Sagar; Tokunbor A Lawal; Carolyn Allen; Muslima S Razaqyar; Monique S Shelton; Irene C Chrismer; Xuemin Zhang; Mary M Cosgrove; Anna Kuo; Ruhi Vasavada; Minal S Jain; Melissa Waite; Dinusha Rajapakse; Jessica W Witherspoon; Graeme Wistow; Katherine G Meilleur
Journal:  J Neurol       Date:  2018-08-28       Impact factor: 4.849

Review 8.  Preclinical model systems of ryanodine receptor 1-related myopathies and malignant hyperthermia: a comprehensive scoping review of works published 1990-2019.

Authors:  Tokunbor A Lawal; Emily S Wires; Nancy L Terry; James J Dowling; Joshua J Todd
Journal:  Orphanet J Rare Dis       Date:  2020-05-07       Impact factor: 4.123

Review 9.  Cored in the act: the use of models to understand core myopathies.

Authors:  Aurora Fusto; Louise A Moyle; Penney M Gilbert; Elena Pegoraro
Journal:  Dis Model Mech       Date:  2019-12-19       Impact factor: 5.758

Review 10.  Critical Role of Intracellular RyR1 Calcium Release Channels in Skeletal Muscle Function and Disease.

Authors:  Erick O Hernández-Ochoa; Stephen J P Pratt; Richard M Lovering; Martin F Schneider
Journal:  Front Physiol       Date:  2016-01-12       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.